These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38937298)

  • 1. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.
    Moein A; Jin JY; Wright MR; Wong H
    Cancer Chemother Pharmacol; 2024 Jun; ():. PubMed ID: 38937298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
    Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
    Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
    Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
    Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
    Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
    Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
    Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
    Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
    Hutchinson KE; Chen JW; Savage HM; Stout TJ; Schimmoller F; Cortés J; Dent S; Harbeck N; Jacot W; Krop I; Trabucco SE; Sivakumar S; Sokol ES; Wilson TR
    Genome Med; 2023 Apr; 15(1):28. PubMed ID: 37101291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
    Grinshpun A; Ren S; Graham N; DeMeo MK; Wrabel E; Carter J; Tayob N; Pereslete A; Hamilton E; Juric D; Mayer EL; Tolaney SM; Krop IE; Metzger O
    ESMO Open; 2024 Jun; 9(6):103465. PubMed ID: 38833970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
    Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
    Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.
    Rusz O; Kószó R; Dobi Á; Csenki M; Valicsek E; Nikolényi A; Uhercsák G; Cserháti A; Kahán Z
    Onco Targets Ther; 2018; 11():5459-5463. PubMed ID: 30233207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
    Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
    Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
    Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.